CALLALY
20.11.2020 12:38:09 CET | Business Wire | Press release
The Tampliner, the period-care innovation created by UK-based B-corp Callaly , has been recognised in TIME’s 100 Best Inventions of 2020 - its annual list of the 100 Best Inventions that are making the world better, smarter and even a bit more fun. Callaly is one of only eight British companies to make this year’s list.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201120005371/en/
Callaly set out to improve the $34bn period care industry with the launch of the Tampliner, a completely new period care product and first design upgrade to the tampon in 90 years. It is a 2-in-1 period product that combines an organic cotton tampon with a soft mini-liner for extra protection against leaks, connected by a ‘virtual applicator’.
The Tampliner, which is designed and manufactured in the UK and was launched in February 2020, was invented by Dr Alex Hooi, a senior British gynaecologist and Fellow of the Royal College of Obstetricians and Gynaecologists and developed by garment technologist Ewa Radziwon, who trained at London College of Fashion.
The British manufactured product is protected by four granted patent families covering 80% of the global market. It is now being exported across Europe in Sweden, the Netherlands and Ireland, and has been trialled with positive results in China.
Callaly, which has raised £13.2m through private investment and government funding, is backed by Innovate UK, having received five tranches totalling £3.9m to support the development and manufacture of the Tampliner. The company employs 20 people in its London HQ.
Callaly’s founder and CEO, Thang Vo-Ta said: “Our whole team is honoured that the Tampliner has been recognised by TIME as a pioneering invention. The period-care industry has been failing people for decades. Little to no R&D in the space means that many people with periods are compromising their health, comfort and convenience, with no choice but to put up with the dissatisfaction they feel. With our 2-in-1 invention we set out to address these problems from every angle and truly make people’s lives better. The Tampliner paves the way for further product innovations to radically improve people’s experiences of periods across the globe.”
Dr Ian Campbell, Executive Chair (Interim) Innovate UK said: "Innovate UK has been proud to support Callaly’s journey over the years, from innovation to manufacturing and now global expansion. This recognition from TIME acknowledges the great potential of R&D-backed British businesses like Callaly to change the world for the better."
Image of the tampliner can be found here .
See the full list here: www.time.com/best-inventions-2020
See the international cover of TIME featuring the 100 Best Inventions of 2020 here: bit.ly/3lJM8ss
ENDS
About Callaly:
British based Callaly is a certified B Corp- a for-profit company that’s committed to using business as a force for good. There are over 3,500 certified B Corps in the world including Danone N. America and Unilever’s Ben & Jerry. Every decision Callaly makes, no matter how small, is taken with an eye on the wider global impact. Callaly donates at least 1% of sales to charities supporting women & children.
Callaly offers a range of high quality period care products managed through its ISO9001 based Quality Management System including award-winning Tampliners, pantyliners, day pads, night pads and tampons- all in a range of different absorbencies. All the products are made with 100% organic cotton and are free from dioxins, perfumes, and pesticides. The Earth-friendly products are all wrapped in sustainable packaging.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201120005371/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
